[Malignant fibrous histiocytoma of the retroperitoneum: an analysis of 31 cases].
OBJECTIVE
To investigate the diagnosis and treatment of malignant fibrous histiocytoma of the retroperitoneum (MFHR).


METHODS
The clinicopathological features, treatment and prognosis of 31 patients with MFHR were retrospectively analyzed.


RESULTS
The mean age of the patients was 52.7 +/- 14.1 years. Male:Female = 22:9. The primary symptoms were abdominal mass and pain. The average diameter of tumor was 15 cm. The histopathologic types of the tumor were inflammatory, storiform-pleomorphic, myxoid and giant cell in 16, 10, 4 and 1 cases. The overall survival rate of 1-, 3- and 5-year was 61.3% +/- 9.8%, 31.6% +/- 11.3% and 21.1% +/- 11.4% with a median survival time of 17.0 +/- 6.3 months. Complete resection of the tumor was the major prognostic factor. Postoperative radiotherapy of 20 - 45 Gy was able to prolong the median survival from 12.1 +/- 11.6 months of surgery alone to 26.4 +/- 22.0 months of surgery plus postoperative radiotherapy though without statistical significance (P = 0.051). Postoperative CHOP chemotherapy was not shown to be beneficial.


CONCLUSIONS
Chemotherapy remains the important method of cure. The survival in patients with MFHR might be improved by complete resection combined with chemotherapy or/and radiotherapy.
Wang
Bao-gui
BG
Department of Abdominal Surgery, Tianjin Cancer Hospital, Tianjin 300060, China. Wangbaogui@hotmail.com
Liang
Han
H
Cui
Qing-hao
QH
Wang
Jia-cang
JC
Liu
Jian-zhong
JZ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018219:Histiocytoma, Benign Fibrous / Q000556:secondary / Q000601:surgery* / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010180:Pancreatectomy; D011184:Postoperative Period; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D012189:Retrospective Studies; D013156:Splenectomy; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone